Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase 1 clinical trial for AVA6000, a novel peptide drug conjugate. The trial, leveraging Avacta’s proprietary pre|CISION technology, has successfully completed the first cohort and initiated dosing for three patients in the second cohort. This advancement is part […]
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful diagnostics, has announced a crucial milestone in its drug development journey. The company has successfully dosed the third patient in the first cohort of the two-weekly Phase 1a dose escalation study of AVA6000. This peptide drug conjugate, […]
